Freudenberg Medical Pushes Medtech Manufacturing Toward Miniaturization and AI Integration
Freudenberg Medical is betting that technical differentiation-not scale alone-will define success in medtech manufacturing over the next five years. The precision component maker, named a finalist for MD+DI's 2026 Company of the Year, is investing in AI agents and automation to reduce product development cycles while redesigning supply chains for regional resilience.
Michael McGee, CEO of Freudenberg Medical, outlined the company's strategy in a recent interview. The medtech industry is moving in two directions simultaneously: devices are getting smaller and lighter, yet their functional density is increasing. That tension is reshaping how component makers approach both materials and manufacturing processes.
Miniaturization Meets Material Science
Freudenberg is seeing demand for components that pack more capability into less material. Microelectronics and microextrusions are converging with traditional metal and polymer work, blurring old category lines. Lightweighting-reducing material thickness and weight-cuts shipping costs, waste, and total material consumption across the supply chain.
"There is less material being used in most of the devices we have, however the functional content, or utility of that material, is increasing," McGee said. The company's micro-molding capabilities are central to this shift, enabling high-precision, low-profile devices across clinical specialties.
Robotics and AI in the Cleanroom
Freudenberg is deploying robotics and optical systems to manage contamination-one of medtech manufacturing's core challenges. Automation handles repetitive, ergonomically difficult tasks while freeing skilled workers for higher-value engineering work.
On the AI side, the company has moved beyond pilots. Freudenberg is using AI-driven modeling to reduce iterations in new product development, compressing timelines from multiple trial cycles to one or two. The company leverages its position within a global conglomerate to access advanced technology platforms, then applies them to medtech applications.
"We have demonstrated proof of concept, and we are now able to scale and deploy these types of technology platforms against different applications," McGee said. Parametric modeling accelerated by larger data sets is already reducing engineering cycles in the new product introduction process.
Supply Chain Regionalization After COVID
The pandemic exposed fragility in globally optimized supply chains. Freudenberg has responded by building redundancy based on geography and regulatory approval. The company now treats supplier relationships as partnerships, investing in forecasting tools and transparency to avoid supply shocks.
A significant shift is happening on the demand side. Sourcing-developing multiple supply options early in product development-is becoming standard practice, though it requires double the upfront work. "Everybody wants to do sourcing, but it's a challenge in order to put their resources on," McGee acknowledged. Newer programs are beginning to commit to this approach, signaling that lessons from COVID are translating into structural change.
Sustainability and End-of-Life Design
Medtech's reliance on single-use devices is drawing regulatory and environmental scrutiny. Freudenberg is rethinking product lifecycles from design through disposal, considering material reduction, disassembly, and recyclability. These decisions are being made early in development, not as afterthoughts.
EU MDR and other evolving frameworks are reinforcing this shift. Regulatory pressure is pushing manufacturers to make conscious trade-offs between global scale and regional compliance, with implications for facility location and supply chain structure.
What's Next
McGee said Freudenberg's core strategy will remain unchanged. The company is family-owned, which means it can take a long-term view without quarterly earnings pressure. What will evolve is footprint expansion and deepening technical leadership.
"The technical differentiation at Freudenberg is what is going to be standing head and shoulders above in the market," he said. That means continued investment in AI for executives and strategy implementation, supply chain resilience, and materials science-not chasing trends.
Your membership also unlocks:
